Fort Lee, New Jersey, USA, March 24, 2015 (GLOBE NEWSWIRE) -- Herborium® Group,
Inc. (OTC Pink: HBRM),
www.Herborium.com, a
Botanical Therapeutics® Company and the provider of unique
all botanical medicines (Botanical Therapeutics®)
announced today that last week its Board of Directors
approved an increase in the number of Company authorized common
shares to 10 billion shares.
Herborium revenues during past two years more than tripled and
the Company is moving forward with expanding its presence in a
number of markets including:
· UK where it is
working with HUT Group, LLC. , the UK's leading multi-website
online retailer of Health and Beauty products
with a goal of £500,000.00 ($785,000.00) in sales within next 18-24
months;
· France, where the
company has increased its sales over 5 fold since 2013;
· Asia, where
Herborium is presently forming valuable market partnerships.
In addition, the company has dramatically
increased its sales through third party platforms like Amazon and
affiliate programs and is expending this strategy to Europe and
Japan.
This rapid growth has opened opportunities for Herborium to look
not only for new markets and distribution channels but also to
develop and acquire new products and enter into new and more mature
business partnerships and alliances. The increase in authorized
common shares supplements our financing objectives to underwrite
these new initiatives.
In addition, this business progress has positioned the Company
to further implement its plan to uplist the trading platform for
its common shares and to return to full SEC reporting status in
2015. Our goal is to increase shareholder value through our
strategic plan to enhance shareholder liquidity.
About Herborium Group, Inc.
Herborium Group, Inc., a botanical therapeutics®
company that develops, license and markets proprietary, botanical
based medicinal products to consumers and healthcare professionals.
The Company business model focuses on emerging market opportunities
spearheaded by the growth of a new market sector located between
high-cost, high-risk, ethical pharmaceuticals and commoditized
classic nutraceuticals (supplements). The Company uses
clinical validation and a proactive regulatory strategy based on
the FDA Guidance for Industry: Botanical Drug Products
(FDA Guidance 2004) to establish and maintain a
differential advantage. Herborium has secured a pipeline of
botanical ingredients based products in the areas of dermatological
needs, wellness and energy, prostate health, women's health and
selected sexual disorders resulting from cardiovascular disease,
use of anti-depressants, diabetes, surgical procedures, and other
problems. Herborium Group sells its products in the United States,
the United Kingdom, and continental Europe through a network of
distributors, specialty retailers, and e-commerce. For more
information, please visit www.herborium.com, www.acnease.com.
www.acnease.fr.
Safe Harbor Statement: This release
contains forward-looking statements with respect to the results of
operations and business of Herborium Group, Group, Inc., which
involves risks and uncertainties. The Company's actual future
results could materially differ from those discussed. The
Company intends that such statements about the Company's future
expectations, including future revenues and earnings, and all other
forward looking statements be subject to the "Safe Harbors"
provision of the Private Securities Litigation Reform Act of
1995.
CONTACT: Herborium Group, Inc.
Email: InvestorsRelations@Herborium.com